Compare Stocks → America could fall from this event (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:BRSHNASDAQ:FRTXNASDAQ:HILS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$2.56$3.88$2.35▼$44.80$1.74M0.45981,133 shs29,167 shsBRSHBruush Oral Care$0.06+5.2%$0.05$0.04▼$9.73$31K1.96.62 million shs2.94 million shsFRTXFresh Tracks Therapeutics$0.90-1.2%$0.91$0.49▼$1.10$5.37M0.3518,057 shs396 shsHILSHillstream BioPharma$0.37-2.6%$0.38$0.19▼$2.65$6.53M3.081.39 million shs310,613 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path-5.88%-5.54%-16.07%-72.40%-91.35%BRSHBruush Oral Care-3.65%-21.62%+24.20%-36.96%-99.25%FRTXFresh Tracks Therapeutics-1.23%-3.11%-1.09%-8.62%+68.56%HILSHillstream BioPharma0.00%+63.17%-2.21%-2.31%-9.81%Biden FINISHED On June 13th? (Ad)Thanks to Biden’s disgraceful leadership we now have sky-high inflation… unchecked immigration… rampant crime… and a “woke mob” hell bent on destroying the America you and I know and love. Biden’s days are numbered.Click here now to see his shocking evidence.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path1.8308 of 5 stars3.53.00.00.02.50.00.6BRSHBruush Oral CareN/AN/AN/AN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.001,462.50% UpsideBRSHBruush Oral CareN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AHILSHillstream BioPharma2.00HoldN/AN/ACurrent Analyst RatingsLatest BRSH, FRTX, BPTH, and HILS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 5/14/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ABRSHBruush Oral CareN/AN/AN/AN/A($4.30) per shareN/AFRTXFresh Tracks Therapeutics$8.01M0.67N/AN/A$1.66 per share0.54HILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/15/2024 (Confirmed)BRSHBruush Oral CareN/AN/A0.00∞N/AN/AN/AN/AN/AFRTXFresh Tracks Therapeutics-$5.69M-$1.41N/A∞N/A-91.29%-60.83%-50.73%N/AHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ALatest BRSH, FRTX, BPTH, and HILS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2024N/ABPTHBio-Path-$4.54N/A+$4.54N/AN/AN/A 3/15/2024Q4 2023FRTXFresh Tracks TherapeuticsN/A-$0.20-$0.20-$0.20N/AN/A3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ABRSHBruush Oral CareN/AN/AN/AN/AN/AFRTXFresh Tracks TherapeuticsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60BRSHBruush Oral CareN/AN/AN/AFRTXFresh Tracks TherapeuticsN/A6.986.98HILSHillstream BioPharmaN/A3.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%BRSHBruush Oral Care31.85%FRTXFresh Tracks Therapeutics25.04%HILSHillstream BioPharma13.36%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%BRSHBruush Oral Care29.81%FRTXFresh Tracks Therapeutics0.23%HILSHillstream BioPharma30.24%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableBRSHBruush Oral Care11510,000359,000Not OptionableFRTXFresh Tracks Therapeutics45.97 million5.96 millionNot OptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableBRSH, FRTX, BPTH, and HILS HeadlinesRecent News About These CompaniesMay 9, 2024 | americanbankingnews.comHillstream BioPharma (NASDAQ:HILS) Shares Up 10.6%April 17, 2024 | morningstar.comHill & Smith PLC HILSOctober 31, 2023 | morningstar.comKiromic BioPharma Inc Ordinary Shares KRBPSeptember 22, 2023 | finance.yahoo.comHillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.September 21, 2023 | finance.yahoo.comDawson James Securities Announces October Date for 8th Annual Small Cap Growth ConferenceSeptember 11, 2023 | finance.yahoo.comHillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic PruritisSeptember 8, 2023 | finance.yahoo.comHillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13August 30, 2023 | benzinga.comHillstream – Drug Maker Licenses Critical New Technology In Fight Against CancerAugust 25, 2023 | seekingalpha.comNMTRQ 9 Meters Biopharma, Inc.August 9, 2023 | finance.yahoo.comHillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023July 20, 2023 | finance.yahoo.comHillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215July 13, 2023 | thepharmaletter.comChange of direction at Hillstream driven by established scienceJuly 10, 2023 | finance.yahoo.comHillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and BiologicsJuly 7, 2023 | thepharmaletter.comHillstream announces new collab to boost early stage researchJuly 6, 2023 | finance.yahoo.comHillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian CancersJune 9, 2023 | finance.yahoo.comHILS - Hillstream BioPharma, Inc.May 15, 2023 | finance.yahoo.comHillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly AndersonMay 4, 2023 | finanznachrichten.deHillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma Announces Closing of Public Offering of Common StockMay 2, 2023 | finance.yahoo.comHillstream BioPharma to Present at Upcoming May 2023 Investor and Industry ConferencesNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Bruush Oral CareNASDAQ:BRSHBruush Oral Care Inc., an oral care company, manufactures and sells electric toothbrushes in the United States and Canada. It offers Brüush starter kit, including electric toothbrush, three brush heads, a magnetic charging stand and USB power adapter, and a travel case. It also provides brush head refills. The company sells its products through its website www.bruush.com. Bruush Oral Care Inc. was incorporated in 2017 and is based in Vancouver, Canada.Fresh Tracks TherapeuticsNASDAQ:FRTXFresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.Hillstream BioPharmaNASDAQ:HILSHillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.